Voyager Therapeutics develops life-changing gene therapies from discovery, preclinical and clinical development, through to commercialization. We focus on people living with severe neurological diseases that lack safe and effective treatment options, particularly in the areas of advanced Parkinson’s disease, monogenic forms of amyotrophic lateral sclerosis (ALS), Huntington’s disease, Friedreich’s ataxia, neurodegenerative diseases related to defective or excess aggregation of tau protein in the brain including Alzheimer’s disease, and severe, chronic pain.
